Latest News

FDA to decide on Spectrum Pharmaceuticals’ neutropenia drug by Oct. 2020

Spectrum said the FDA had accepted its application for Rolontis, which had shown non-inferiority to Amgen’s Neulasta in Phase III testing. However, oncologists expressed mixed opinions about the drug.

Source link

Related posts

Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma


Global Transplant Diagnostics Market Expected to Grow with a CAGR of 6% Over the Forecast Period, 2019-2025 –


Chronic kidney disease patients face continual, significant gaps in care


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy